Cited 0 time in
Cevidoplenib (SKI-O-703), a novel specific SYK inhibitor, reduces antiphospholipid antibody titers and prevents intramyocardial small arterial thrombosis in a mouse model of primary antiphospholipid syndrome
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 윤지희 | - |
| dc.date.accessioned | 2024-12-01T14:30:42Z | - |
| dc.date.available | 2024-12-01T14:30:42Z | - |
| dc.date.issued | 2023-09-14 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/198929 | - |
| dc.title | Cevidoplenib (SKI-O-703), a novel specific SYK inhibitor, reduces antiphospholipid antibody titers and prevents intramyocardial small arterial thrombosis in a mouse model of primary antiphospholipid syndrome | - |
| dc.type | Conference | - |
| dc.citation.conferenceName | KAI International Meeting 2023 | - |
| dc.citation.conferencePlace | Sondo Convensia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
